RE
SMMT icon

RBC Europe’s Summit Therapeutics SMMT Stock Holding History

RBC Europe’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,716
Closed -$18.6K – 1066
2021
Q3 		$18.6K Hold
3,716
– – ﹤0.01% 806
2021
Q2 		$27.7K Buy
3,716
+546
+17% +$3.58K ﹤0.01% 734
2021
Q1 		$18.6K Buy
3,170
+1,200
+61% +$7.74K ﹤0.01% 784
2020
Q4 		$9.26K Buy
+1,970
New +$8.34K ﹤0.01% 891

Other funds holding SMMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

RBC Europe's SMMT Position: Q4 2021 in Review

RBC Europe sold out of Summit Therapeutics (SMMT) in Q4 2021, closing a stake of 3,716 shares — an estimated $18.6K sold.

RBC Europe first reported a position in SMMT in Q4 2020 and held it in 4 quarters. The position peaked at $27.7K in Q2 2021. 55 funds tracked by Wall St. Rank hold SMMT as of Q4 2021.

  • RBC Europe reported no remaining Summit Therapeutics position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 3,716 Summit Therapeutics shares in Q4 2021, an estimated $18.6K.
  • RBC Europe first reported a position in Summit Therapeutics in Q4 2020 and held it in 4 quarters.
  • RBC Europe's Summit Therapeutics position peaked at $27.7K in Q2 2021.
  • 55 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.